WoodsJDPortFK. The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant. 1997;12(4):657–659.
2.
AndrassyKMallucheHBornefeldH. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study. Klin Wochenschr. 1974;52(7):348–349.
3.
SaranRDykstraDMWolfeRAGillespieBHeldPJYoungEWDialysis Outcomes and Practice Patterns Study. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2002;40(6):1255–1263.
4.
WindusDWSantoroSAAtkinsonRRoyalHD. Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts. Am J Kidney Dis. 1997;29(4):560–564.
5.
GhorbaniAAalamshahMShahbazianHEhsanpourAArefA. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol. 2009;19(2):57–61.
6.
DemberLMBeckGJAllonMDialysis Access Consortium Study Group. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299(18):2164–2171.
7.
GrontoftKCLarssonRMulecHWeissLGDickinsonJP. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol. 1998;32(4):276–283.
8.
YevzlinASConleyELSanchezRJYoungHNBeckerBN. Vascular access outcomes and medication use: a USRDS study. Semin Dial. 2006;19(6):535–539.
9.
HasegawaTElderSJBragg-GreshamJL. Consistent aspirin use is associated with improved arteriovenous fistula survival among incident hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol. 2008;3(5):1373–1378.
10.
WeissMFScivittaroVAndersonJM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37(5):970–980.
11.
GrosserNSchroderH. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol. 2003;23(8):1345–1351.
12.
IkonomidisIAndreottiFEconomouEStefanadisCToutouzasPNihoyannopoulosP. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100(8):793–798.
13.
KaufmanJSO’ConnorTZZhangJHVeterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14(9):2313–2321.
14.
DixonBSBeckGJVasquezMADAC Study Group. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009;360(21):2191–2201.
15.
OsbornGEscofetXDa SilvaA. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2008;4:CD002786.
16.
FoleyRNParfreyPSSarnakMJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12)(suppl):S16–S23.
17.
MaitraSSekerciogluNBalochSCookWLJassalSV. Causes of death in older peritoneal dialysis patients–can we depend on registry reports?. Int Urol Nephrol. 2007;39(1):345–350.
18.
SoubassiLPChirasTCPapadakisED. Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis. Int Urol Nephrol. 2006;38(3-4):795–800.
19.
K/DOQIWorkgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4)(suppl 3):S1–S153.
20.
ParaskevasKIStathopoulosVMikhailidisDP. Pleiotropic effects of statins: implications for a wide range of disease. Curr Vasc Pharmacol. 2008;6(4):237–239.
21.
ParaskevasKITzovarasAABrianaDDMikhailidisDP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des. 2007;13(35):3622–3636.
22.
ParaskevasKIGiannoukasADMikhailidisDP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg. 2009;23(5):690–699.
23.
ParaskevasKILiapisCDHamiltonGMikhailidisDP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. Eur J Vasc Endovasc Surg. 2006;32(3):286–293.
24.
ParaskevasKIAthyrosVGBrianaDDKakafikaAKaragiannisAMikhailidisDP. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets. 2007;8(8):942–951.
25.
PorterKETurnerNA. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans. 2002;30(2):120–126.
26.
PorterKENaikJTurnerNADickinsonTThompsonMMLondonNJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg. 2002;36(1):150–157.
27.
HenkePBlackburnSProctorMC. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg. 2004;39(2):357–365.
28.
AbbruzzeseTAHavensJBelkinM. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg. 2004;39(6):1178–1185.
29.
RighettiMFerrarioGSerbelloniPMilaniSTommasiA. Some old drugs improve late primary patency rate of native arteriovenous fistulas in hemodialysis patients. Ann Vasc Surg. 2009;23(4):491–497.
30.
PisoniRBarker-FinkelJAlloM. Statin therapy is not associated with improved vascular access outcomes. Clin J Am Soc Nephrol. 2010;5(8):1447–1450.
31.
ChouCYKuoHLYungYFLiuYLHuangCC. C-reactive protein predicts vascular access thrombosis in hemodialysis patients. Blood Purif. 2006;24(4):342–346.
32.
ParaskevasKIMikhailidisDP. C-reactive protein (CRP): more than just an innocent bystander?. Curr Med Res Opin. 2008;24(1):75–78.
33.
TsiaraSElisafMMikhailidisDP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19(6):540–556.
34.
MilionisHJRizosEKostapanosM. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006;22(6):1123–1131.
35.
AthyrosVGMikhailidisDPDidangelosTP. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Curr Med Res Opin. 2006;22(5):873–883.
36.
PrasadK. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006;24(1):33–50.
37.
AndreucciVEFissellRBBragg-GreshamJL. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis. 2004;44(5)(suppl 2):61–67.
38.
WannerCKraneVMarzWGerman Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248.
39.
FellstromBCJardineAGSchmiederREAURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407.
SharathkumarAHirschlRPipeSCrandellCAdamsBLinJJ. Primary thromboprophylaxis with heparins for arteriovenous fistula failure in pediatric patients. J Vasc Access. 2007;8(4):235–244.
42.
SchmitzPGMcCloudLKReikesSTLeonardCLGellensME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002;13(1):184–190.
43.
IrishADograGMoriT. Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrol. 2009;10:1.
